Members matter ...
Upcoming CareFirst Formulary Updates and Medications Added to Prior Authorization List
Carefirst has issued a Medical Preferred Drug Strategy Update effective August 1, 2024. Below is a summary of the factor agents affected. Learn what this means for affected patients.
Octapharma USA: FDA Grants Orphan Drug Exclusivity to wilate®, the First VWF Concentrate for Prophylaxis in All Types of VWD
PARAMUS, NJ. 29/04/2024. PRESS RELEASE Octapharma USA, Inc. announced the U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity for wilate®, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection, for routine prophylaxis
Advocating for Marylanders since 1950
The Hemophilia Foundation of Maryland evolved in the early 1950’s from a group of concerned families. These early chapter families were brought together by the social worker at St. Agnes Hospital, where most were treated. Some of the founding members of this organization continue to guide HFM today.
Our Foundation's History of Advocacy
- Increasing awareness and understanding of bleeding disorders
- Advocating for a safe blood supply to ensure the integrity of clotting factor concentrates and other treatments for individuals with bleeding disorders
- Ensuring access to comprehensive care centers that provide specialized treatment and support services
- Advocating for affordable access to clotting factor concentrates and other essential medications
- Promoting research funding for innovative treatments
- Addressing disparities in healthcare access and quality for individuals with bleeding disorders, particularly in underserved communities
- Supporting policies that protect the rights of individuals with bleeding disorders, including anti-discrimination laws and healthcare coverage mandates
- Raising awareness about the challenges and needs of individuals living with a bleeding disorder to foster understanding and support within the broader community
- Collaborating with healthcare providers, researchers, policymakers, and advocacy organizations to advance the interests of bleeding disorder patients and improve their quality of life
- Promoting mental health support for bleeding disorder patients
